Skip to content

Cencora COR Free cash flow

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Cardinal Health logo
Cardinal HealthCAH
$1.68B-40.0%
McKesson logo
McKessonMCK
$3.31B-56.3%
United Parcel Service, Inc. logo
United Parcel Service, Inc.UPS
$1.19B-17.3%
CryoPort, Inc. logo
CryoPort, Inc.CYRX
-$6.25M+16.8%
AbbVie logo
AbbVieABBV
$3.56B+155%

Other financials

Income statement

See full
Revenue$78.4B+3.8%
Gross profit$3.6B+17.3%
Operating income$1.1B+10.3%
Net income$1.6B+129%
EPS (diluted)$8.40+128%

Balance sheet

See full
Cash & equivalents$2.2B+10.0%
Total debt$12.2B+71.9%
Total equity$3.4B+235%
Total assets$81.7B+14.7%

Cash flow

See full
Operating cash flow-$2.3B+15.2%
CapEx$165.6M+28.3%

Valuation

See full
Market cap$55.83B-1.9%
Enterprise value$65.84B+6.1%
P/E15.5×+3.1×
P/S0.2×0.0×

Profitability

See full
Gross margin3.8%+0.4pp
Operating margin0.8%0.0pp
Net margin0.6%-0.1pp
FCF margin1.1%+1.0pp

Returns & leverage

See full
Return on equity130.6%-99.8pp
Debt / equity3.6×-3.4×
Current ratio0.9×+0.1×

Where this comes from

Calculated from Cencora’s reported figures.

The official record: Cencora’s 10-Q, filed February 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cencora's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cencora's free cash flow?
Cencora (COR) reported free cash flow of -$2.42B in Q4 2025.
How has Cencora's free cash flow changed year-over-year?
Cencora's free cash flow increased by 14.2% year-over-year, from -$2.82B to -$2.42B.
What is the long-term trend for Cencora's free cash flow?
Over 3 years (2022 to 2025), Cencora's free cash flow has grown at a 14.1% compound annual growth rate (CAGR), from $2.21B to $3.28B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.